

European Partnership for Personalised Medicine (EP PerMed)

EP PerMed background, proposal development, SRIA and timeline

Wolfgang Ballensiefen

German Aerospace Center, DLR

EP PerMed Writing Group


1st European Partnerships (EP) in the Cluster Health

(1) Innovative Health Initiative (IHI)	2022-2029	IMI
(2) EU-Africa Global Health	2022-2029	EDCTP
(3) Transformation of Health Care Systems (THCS)	2023-2030	JPI AAL, MYBL & CSA To Reach, ...
(4) Partnership for the Assessment of Risk from Chemicals “PARC”	2022-2029	JPI HBM4EU
(5) ERA for Health (ERA4Health)	2022-2029	JPI HDHL, ERA CVD & EuroNanoMed, ...
(6) Rare Diseases	2024-2031	E-Rare, EJP RD
(7) One-Health Anti-Microbial Resistance	2024-2031	JPI AMR & One Health
(8) Pandemic Preparedness	2024-2031	-
(9) Personalised Medicine (EP PerMed)	2023-2030	ERA PerMed & ICPeMed + Family

European Partnership for Personalised Medicine - EP PerMed

IC PerMed-related initiatives supporting EP PerMed:

- **ICPerMed &**
- **ERA PerMed** as well as the so called
- “**ICPerMed Family**” of Coordination and Support Actions
 - **4** dedicated to the communication & cooperation with
 - Latin American & Caribbean (**EULAC PerMed**)
 - China (**Sino-EU PerMed/IC2PerMed**)
 - Africa (**EU-Africa PerMed**)
 - **2** focus/ed on European Regions (**R4PerMed/SAPHIRE**)
 - **2** with research connected topics (**HEcoPerMed/PERMIT**)
 - **1** on Personalised Prevention (**PROPHET**)



EP PerMed preparing activities - 1

- **Preparatory Group** of ICPerMed, ERA PerMed & EC (2020-21)
- ICPerMed **Information Day** for EP PerMed in May 2021
- Start of a **EC & Member States Group** and a **Drafting sub-Group** (dg, 09/21)
- EP PerMed **draft proposal** of the dg/EC is published by the EC (02/22)
- Development of a 1st *Strategic Research and Innovation Agenda*, **SRIA** by the dg/EC & experts/stakeholders (11/2021, updates are planned)
- 1st EP PerMed **budget request** at Member State level by the EC (summer 2022)

EP PerMed preparing activities - 2

- Start of the proposal **Writing Group (WG, 11/22, EP PerMed partners)**
- European Partnership for Personalised Medicine **call** by the EC (06/12/2022)
- EP PerMed **proposal submission**, incl. 2024 annual work plan (13/04/23)
- In parallel the 1st version of the **SRIA** (04/23) has to be published
- **EP PerMed start** after a positive EC/HADEA review & a signed GA/CA (~Q4/23)
- Publication of the 1st of 7 Joint Transnational Calls (**JTC**) (~ Q1/24)
- EP PerMed webpage and further EP PerMed activities and events (2024-2030)

EP PerMed Draft Proposal

Developed by the dg & published by the EC as well as ICPerMed and ERA PerMed (02/22)

https://www.icpermed.eu/media/content/Final_draft%20proposal%20EP%20PerMed.pdf

The EP PerMed EC call of is open: *HORIZON-HLTH-2023-CARE-08-01*

Draft proposal for a European Partnership under Horizon Europe: European Partnership for Personalised Medicine

EP PerMed

Version 2, January 2022

About this draft

In the course of summer 2021, Commission services asked potential partners to further elaborate proposals for the 2023/24 candidate European Partnerships identified during the strategic planning of Horizon Europe. These proposals have been developed by potential partners based on common guidance and template, considering the initial concepts developed by the Commission and feedback received from Member States during early consultation¹. The Commission Services have guided revisions during drafting to facilitate alignment with the overall EU political ambition and compliance with the criteria for Partnerships.

This document is a stable draft of the partnership proposal, released for the purpose of ensuring transparency of information on the current status of preparation (incl. on the process for developing the Strategic Research and Innovation Agenda, SRIA). As such, it aims to contribute to further collaboration, synergies and alignment between partnership candidates, as well as more broadly with related R&I stakeholders in the EU, and beyond where relevant. This informal document does not reflect the final views of the Commission, nor pre-empt the formal decision-making (comitology or legislative procedure) on the establishment of European Partnerships.

In the next steps of preparations, the Commission Services will further assess these proposals against the selection criteria for European Partnerships. The final decision on launching a Partnership will depend on progress in their preparation (incl. compliance with selection criteria) and the formal decisions on European Partnerships (linked with the adoption of Strategic Plan, work programmes, and legislative procedures, depending on the form). Key precondition is the existence of an agreed Strategic Research and Innovation Agenda / Roadmap. The launch of a Partnership is also conditional to partners signing up to final, commonly agreed objectives and committing the resources and investments needed from their side to achieve them.

Expected **outcomes** from the EC call - **1a**

- European countries and regions, along with international partners, are engaged in enhanced collaborative research efforts for the development of innovative PM approaches regarding prevention, diagnosis and treatment;
- Healthcare authorities, policymakers and other stakeholders develop evidence-based strategies and policies for the uptake of PM in national or regional healthcare systems;
- Health industries, policymakers and other stakeholders have access to efficient measures and investments to allow swift transfer of research and innovation into market;
- Health industries and other stakeholders can accelerate the uptake of PM through the adoption of innovative business models;

Expected **outcomes** from the EC call - **1b**

- Healthcare authorities, policymakers and other stakeholders use improved knowledge and understanding of the health and costs benefits of PM to optimise healthcare and make healthcare systems more sustainable;
- Healthcare providers and professionals improve health outcomes, prevent diseases and maintain population health through the implementation of PM;
- Stronger and highly connected local/regional ecosystems of stakeholders, including innovators, are in place and facilitate the uptake of successful innovations in personalised medicine, thus improving healthcare outcomes and strengthening European competitiveness;
- Citizens, patients and healthcare professionals have a better knowledge of PM and are better involved in its implementation;
- Stakeholders cooperate better and establish a network of national and regional knowledge hubs for PM.

Activities expected from the EC call

- The European Partnership for Personalised Medicine is to be implemented through a joint programme of activities ranging from research to coordination & networking activities, including training, demonstration, piloting and dissemination activities, to be structured along the following main building blocks:
- Joint implementation of the SRIA;
- Joint annual calls for R&I activities, applied R&I, pilots;
- Capacity building activities;
- Activities to enhance the skills of the relevant personalised medicine workforce, and improve citizen relevant awareness and literacy;
- Deployment activities through pilots, innovation procurement and financial support mechanisms,
- Flanking measures

European Partnership for Personalised Medicine - EP PerMed



Expected Budget and Examples of Activities developed according to the Writing Group

- **Member States** (incl. regions) and the **EC** will invest **over 300 Mio. €** to support transnational calls, other activities of EP PerMed & its management for **7-10 years**.
- Minimum **7** co-funded **PM-related Joint Transnational Calls**, comparable to the 5 implemented by ERA PerMed (2018-2022), will be developed, executed & monitored.
- Additionally **networking** and **pilot calls** are planned to support the development of innovative PM approaches and their sustainable implementation into health systems.
- The partnership aims to be the major **communication** and **event platform for PM** in cooperation with ICPerMed other initiatives and the EC.
- EP PerMed will communicate and align its activities with the other **European Partnerships** of the Health Cluster & related initiatives/projects in Europe and beyond.

Strategic Research & Innovation Agenda (**SRIA**) supporting activities



The **SRIA** will identify gaps, needs and challenges as well as opportunities and visions which need to be addressed, overcome or reached to foster PM for the benefit of patients & citizens within sustainable health systems.

In addition to the expertise of all involved initiatives & partners and selected strategic documents, the following activities were performed to gather information and ideas for EP PerMed and its SRIA:

- Over **65 interviews** with international PM experts and stakeholders were completed by the dg along guiding questions
- So called: “**Triplets of Action, short ToA**” were identified
- With a 1st set of 47 ToA an **online consultation** was performed by the dg (12/22)
- **Finally, this [ICPerMed workshop](#) collects crucial input for EP PerMed & its SRIA**

The Goals of this ICPeMed Workshop in support of EP PerMed



1. Support of the SRIA development and EP PerMed activities by key note lectures, the winners of the ICPeMed Recognition 2022 and 4 plenary panel discussion each 75min. dedicated to the following Personalised Medicine related topics:
 - a. *Patient and citizen engagement and education*
 - b. *Regional and international perspectives of PM*
 - c. *The PM innovation system and industrial collaboration*
 - d. *Health systems providers, payers, insurances and medical societies*

Do you have Questions?

You are also welcome to contact us or other representatives of the SRIA drafting group or the proposal Writing Group in the case of questions!

Contact: EPerMed@dlr.de or directly

Monika Frenzel, ANR, France and

Wolfgang Ballensiefen, DLR, Germany